Erratum: Antigen-activated dendritic cells ameliorate influenza A infections (Journal of Clinical Investigation (2013) 123:7 (2850-2861) DOI: 10.1172/JCI67550);Antigen-activated dendritic cells ameliorate influenza A infections

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 2850-2861

  Boonnak, Kobporn ^a   Vogel, Leatrice ^a   Orandle, Marlene ^a   Zimmerman, Daniel ^b   Talor, Eyal ^b   Subbarao, Kanta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CEL SCI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; INFLUENZA VIRUS HA PROTEIN; INFLUENZA VIRUS M PROTEIN; INFLUENZA VIRUS NP PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG SYNTHESIS; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84879641177     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI141834     Document Type: Erratum

References (42)

1. Govorkova EA, McCullers JA. Therapeutics against influenza. Curr Top Microbiol Immunol. 2013;370:273-300.
2. van der Vries E, Schutten M, Boucher CA. The potential for multidrug-resistant influenza. Curr Opin Infect Dis. 2011;24(6):599-604.
3. Baranovich T, Webster RG, Govorkova EA. Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr Opin Virol. 2011;1(6):574-581.
4. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358(3):261-273.
5. Le QM, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437(7062):1108. (Pubitemid 41509341)
6. Storms AD, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-2011. Emerg Infect Dis. 2012;18(2):308-311.
7. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol. 2007;81(22):12418-12426. (Pubitemid 350085855)
8. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(suppl 1):S3-S13.
9. Parham P, Androlewicz MJ, Holmes NJ, Rothenberg BE. Arginine 45 is a major part of the antigenic determinant of human beta 2-microglobulin recognized by mouse monoclonal antibody BBM.1. J Biol Chem. 1983;258(10):6179-6186.
10. Rosenthal KS, Taylor P, Zimmerman DH. J-LEAPS peptide and LEAPS dendritic cell vaccines. Microb Biotechnol. 2012;5(2):203-213.
11. Uger RA, Barber BH. Creating CTL targets with epitope-linked beta 2-microglobulin constructs. J Immunol. 1998;160(4):1598-1605. (Pubitemid 28106443)
12. Uger RA, Chan SM, Barber BH. Covalent linkage to beta2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes. J Immunol. 1999;162(10):6024-6028. (Pubitemid 29314960)
13. White J, Crawford F, Fremont D, Marrack P, Kappler J. Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma. J Immunol. 1999;162(5):2671-2676. (Pubitemid 29309288)
14. Zimmerman DH, Rosenthal KS. The L.E.A.P.S. approach to vaccine development. Front Biosci. 2005;10:790-798.
15. Rosenthal KS, Mao H, Horne WI, Wright C, Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine. 1999;17(6):535-542. (Pubitemid 29071084)
16. Goel N, Rong Q, Zimmerman D, Rosenthal KS. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine. 2003;21(27-30):4410-4420. (Pubitemid 37130280)
17. Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci. 2005;10:966-974.
18. Tscherne DM, Garcia-Sastre A. Virulence determinants of pandemic influenza viruses. J Clin Invest. 2011;121(1):6-13.
19. Kobasa D, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007;445(7125):319-323. (Pubitemid 46122819)
20. de Jong MD, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203-1207.
21. Taylor PR, et al. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine. 2010;28(34):5533-5542.
22. Cihakova D, et al. L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. Int Immunopharmacol. 2008;8(5):624-633.
23. Zimmerman DH, et al. CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int Immunopharmacol. 2010;10(4):412-421.
24. Memoli MJ, et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis. 2010;203(3):348-357.
25. Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother. 2009;53(7):3088-3096.
26. Zimmerman DH, Steiner H 3rd, Carmabula R, Talor E, Rosenthal KS. LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. J Vaccines Vaccin. 2012;3(5):149.
27. Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. Annu Rev Immunol. 2009;27:61-82.
28. Marsolais D, et al. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol Pharmacol. 2008;74(3):896-903.
29. Marsolais D, et al. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A. 2009;106(5):1560-1565.
30. Walsh KB, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108(29):12018-12023.
31. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res. 2011;51(1):15-25.
32. Teijaro JR, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980-991.
33. Pulendran B. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol Res. 2004;29(1-3):187-196. (Pubitemid 38822408)
34. Monteiro JM, Harvey C, Trinchieri G. Role of interleukin-12 in primary influenza virus infection. J Virol. 1998;72(6):4825-4831. (Pubitemid 28215659)
35. Charoenvit Y, Goel N, Whelan M, Rosenthal KS, Zimmerman DH. CEL-1000 - a peptide with adjuvant activity for Th1 immune responses. Vaccine. 2004;22(19):2368-2373. (Pubitemid 38757331)
36. Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell Immunol. 2010;262(1):1-5.
37. Inaba K, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-1702.
38. Lutz MB, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77-92. (Pubitemid 29096240)
39. Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, Subbarao K. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol. 2007;81(19):10558-10566. (Pubitemid 47463329)
40. Lau YF, Tang LH, McCall AW, Ooi EE, Subbarao K. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol. 2010;84(17):8639-8649.
41. Lau YF, Santos C, Torres-Velez FJ, Subbarao K. The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines. J Virol. 2011;85(1):76-85.
42. Chen J, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289-1301.